ABSTRACT
BACKGROUND: Antizyme is a critical regulator of cellular polyamine levels due to its effect on polyamine transport and its ability to target ornithine decarboxylase for degradation. Antizyme expression is autoregulatory, through dependence on an unusual +1 translational frameshift mechanism that responds to polyamine levels. RESULTS: HEK293 cells were depleted of polyamines by treatment with an ornithine decarboxylase inhibitor, difluoromethylornithine (DFMO), and grown in the presence or absence of exogenous polyamines prior to the analysis of ribosomal frameshifting levels. Results obtained using an optimized dual luciferase assay system reveal a 10-fold dynamic range of frameshifting, which correlates positively with polyamine addition. Polyamine addition to cells, which have not been pre-treated with DFMO, also resulted in an increase in antizyme frameshifting but to a lesser degree (1.3 to 1.5-fold). In addition, the constructs with the 3' deletion were more responsive to stimulation by polyamine addition than those with the 5' deletion. CONCLUSIONS: The observed regulation of antizyme frameshifting demonstrates the efficiency of a polyamine homeostatic mechanism, and illustrates the utility of a quantifiable cell-based assay for the analysis of polyamines or their analogues on translational frameshifting.
Subject(s)
Frameshift Mutation , Gene Expression Regulation, Enzymologic/genetics , Proteins/genetics , Animals , Base Sequence , Biogenic Polyamines/metabolism , Cell Culture Techniques , Cell Line , DNA , Eflornithine/pharmacology , Humans , Molecular Sequence Data , Proteins/antagonists & inhibitorsABSTRACT
In this paper we describe the synthesis and characterization of a series of simple spermine/amino acid conjugates, some of which potently inhibit the uptake of spermidine into MDA-MB-231 breast cancer cells. The presence of an amide in the functionalized polyamine appeared to add to the affinity for the polyamine transporter. The extensive biological characterization of an especially potent analogue from this series, the Lys-Spm conjugate (31), showed this molecule will be an extremely useful tool for use in polyamine research. It was shown that the use of 31 in combination with DFMO led to a cytostatic growth inhibition of a variety of cancer cells, even when used in the presence of an extracellular source of transportable spermidine. It was furthermore shown that this combination effectively reduced the cellular levels of putrescine and spermidine while not affecting the levels of spermine. These facts together with the nontoxic nature of 31 make it a novel lead for further anticancer development.
Subject(s)
Amino Acids/chemistry , Antineoplastic Agents/chemical synthesis , Lysine/chemical synthesis , Spermidine/antagonists & inhibitors , Spermine/analogs & derivatives , Spermine/chemical synthesis , Antineoplastic Agents/pharmacology , Biological Transport , Drug Interactions , Drug Screening Assays, Antitumor , Eflornithine/pharmacology , Humans , Lysine/analogs & derivatives , Lysine/pharmacology , Ornithine Decarboxylase Inhibitors , Putrescine/metabolism , Spermidine/metabolism , Spermine/metabolism , Spermine/pharmacology , Structure-Activity Relationship , Tumor Cells, CulturedABSTRACT
Polyamines are ubiquitous molecules with multiple intracellular functions. Cells tightly regulate their levels through feedback mechanisms affecting synthesis, intracellular conversion, and transport. Because polyamines have an important role in regulating cell growth, they are a target for cancer therapeutic development. However, to effectively inhibit cell growth through polyamine depletion one needs to inhibit both polyamine synthesis and import. Although the mammalian polyamine transporter has not been cloned, we have identified ORI 1202, an N(1)-spermine-L-lysinyl amide, as an effective polyamine transport inhibitor. ORI 1202 prevents the cellular accumulation of [(3)H]spermidine over a 20-h test period. ORI 1202 (30-100 microM) effectively inhibits cell growth when used in conjunction with the polyamine synthesis inhibitor alpha-difluoromethylornithine (DFMO; > or =230 microM). Human breast, prostate, and bladder carcinoma cell lines and melanoma cell lines show ORI 1202 EC(50) values in the low micromolar range when tested in conjunction with DFMO. This cytostatic effect correlates with a reduction in the intracellular levels of putrescine and spermidine. When ORI 1202 (45 mg/kg, i.p., tidx5) and DFMO (1% in drinking water) were delivered over 14 days, MDA-MB-231 breast tumor xenografts in nude mice showed 50% growth inhibition. Polyamine depletion therapy provides a cytostatic therapy that could be useful against cancer and other diseases resulting from uncontrolled cell growth.
Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Cell Division/drug effects , Eflornithine/pharmacology , Lysine/analogs & derivatives , Polyamines/metabolism , Spermine/analogs & derivatives , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/therapeutic use , Biological Transport/drug effects , Female , Humans , Indicators and Reagents , Kinetics , Lysine/chemical synthesis , Lysine/pharmacology , Lysine/therapeutic use , Male , Melanoma , Mice , Mice, Nude , Molecular Structure , Prostatic Neoplasms , Spermidine/metabolism , Spermine/chemical synthesis , Spermine/pharmacology , Spermine/therapeutic use , Tumor Cells, Cultured , Urinary Bladder Neoplasms , Xenograft Model Antitumor AssaysABSTRACT
The prostate gland has among the highest level of polyamines in the body and prostate carcinomas have even greater elevated polyamine levels. These ubiquitous molecules synthesized by prostate epithelium are involved in many biochemical processes including cellular proliferation, cell cycle regulation, and protein synthesis. These properties have made polyamines a potential target for therapeutic intervention in diseases of excessive cell proliferation such as cancer. However, attempts to limit tumor growth by inhibition of polyamine synthesis have not been very successful since cells have the capacity to take up polyamines from the bloodstream. We report here studies utilizing polyamine depletion by means of a combination of blockade of polyamine synthesis with DFMO (alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase, the rate limiting enzyme in the polyamine synthetic pathway, and ORI 1202, a novel inhibitor of polyamine transport into the cell. This cytostatic combination, even in the presence of excess extracellular polyamines, significantly slowed the growth of the human tumor cell line PC-3 grown in tissue culture with an EC(50) in the &mgr;M range. Other prostate cell lines were similarly growth inhibited including LNCaP.FGC and DU145. Growth of the PC-3 tumor cell line as a xenograft in nude mice was also slowed significantly by this combination of compounds. Polyamine levels in the tumor were lowered from control tumor levels. This combination therapy could provide an effective and potentially non-toxic therapy for prostate tumors.Prostate Cancer and Prostatic Diseases (2000) 3, 275-279
ABSTRACT
The effectiveness of endogenous or exogenously administered colony-stimulating factors may be modulated by the presence of hematopoietic inhibitory molecules. Cytotoxic therapy may result in the induction of hematopoietic inhibitors contributing to prolonged myelosuppression, whereas preventing the induction of such inhibitors may accelerate multilineage recovery. Lisofylline [LSF; (R)-1-(5-hydroxyhexyl)-3,7, dimethyl-xanthine], inhibits the signaling and/or release of certain hematopoietic inhibitory molecules such as tumor necrosis factor alpha, macrophage inflammatory protein 1 alpha, transforming growth factor beta, and IFN-gamma. Treatment of murine bone marrow cells with the cytotoxic agent 5-fluorouracil (5-FU) results in the release of a nondialyzable inhibitor of progenitor (colony-forming unit-granulocyte macrophage; CFU-GM) proliferation. When murine bone marrow cells were treated with 5-FU plus LSF, release of this inhibitor of CFU-GM proliferation was blocked. Neutralizing antibody and Western blot analysis indicated that the inhibitor was TGF-beta. We tested the effect of LSF (100 mg/kg i.p., b.i.d.) on multilineage regeneration after high-dose 5-FU or thiotepa treatment in BALB/c mice. In 4 of 5 experiments, LSF significantly accelerated neutrophil recovery (P < or = 0.05, Wilcoxon paired-signed test). In addition, platelet, reticulocyte, and CFU-GM regeneration were significantly accelerated in mice treated with LSF compared to control mice (P < or = 0.05). LSF had no significant effects on the ability of 5-FU to kill hematopoietic progenitor cells, nor did LSF stimulate or inhibit proliferation of CFU-GM. LSF had no effect on chemotherapy-induced killing of tumor cells in vitro, nor on the antitumor activity of 5-FU or thiotepa in BALB/c mice implanted with P388 leukemia cells. Inhibition of hematopoietic inhibitor release may accelerate multilineage recovery after cytotoxic therapy and, as such, may represent an alternative or additional therapy to the use of positively acting lineage specific colony-stimulating factors.
Subject(s)
Antimetabolites, Antineoplastic/toxicity , Fluorouracil/toxicity , Hematopoiesis/drug effects , Pentoxifylline/analogs & derivatives , Transforming Growth Factor beta/metabolism , Animals , Cell Differentiation/drug effects , Cell Division/drug effects , Colony-Forming Units Assay , Drug Antagonism , Female , Mice , Mice, Inbred BALB C , Pentoxifylline/pharmacologyABSTRACT
During the replicative cycle of many double-stranded RNA viruses, transcription of particles with a double-stranded RNA genome alternates with replication of particles containing a single-stranded genome. In virions infecting some strains of Leishmania guyanensis the putative transcriptase and replicase activities of the RNA-dependent RNA polymerase were previously detected in vitro. Northern hybridization to RNA of known polarity demonstrates that the single-stranded RNA products are of positive polarity and, by definition, are the products of the viral transcriptase. Re-evaluation of previously published data in the light of these findings suggests that transcription in Leishmania viruses is conservative. Sedimentation in sucrose gradients revealed two types of viral particles; single-stranded RNA particles comprised a small fraction of the virus population and sedimented more slowly than the peak of double-stranded RNA particles. In agreement with the replicative model of other dsRNA viruses, these single-stranded particles co-purified with the viral replicase activity that resulted in double-stranded RNA synthesis. In virus-infected promastigote extracts replicase activity decreased with increasing parasite density in culture, suggesting a correlation between cell division and viral replication.
Subject(s)
Leishmania braziliensis/microbiology , RNA Viruses/genetics , RNA, Viral/genetics , Virus Replication/genetics , Animals , Blotting, Northern , Centrifugation, Density Gradient , DNA-Directed RNA Polymerases/metabolism , Polymerase Chain Reaction , RNA Viruses/enzymology , RNA Viruses/physiology , RNA, Double-Stranded/genetics , RNA-Dependent RNA Polymerase/metabolism , Transcription, Genetic/geneticsABSTRACT
The murine B cell lymphoma, 70Z/3, serves as a model for the L chain activation seen when normal B cells develop from pre-B into B cells. 70Z/3 cells can be induced to activate transcription of their endogenous kappa L chain by exposure to exogenous factors in vitro, such as LPS and IFN-gamma. In order to study the interaction of transacting factors with sequences of the kappa gene responsible for their activation, altered kappa genes could be introduced into 70Z/3 cells and their induction patterns studied. As a preliminary step to such studies, we show that wild-type kappa genes stably integrated into 70Z/3 cells can be expressed normally and that their pattern of induction by LPS and IFN-gamma is indistinguishable from wild-type 70Z/3 cells. By using electroporation, gamma genes were co-transfected with either the neo or gpt selectable genes. In all cases, the expression of the kappa genes was autonomous, reflecting neither regulation by the selected markers nor by flanking chromosome sequences. A noninducible variant of 70Z/3, NN12, also increased mRNA levels from transfected kappa genes in response to LPS and IFN-gamma, suggesting that its defect is in its endogenous kappa gene. These results demonstrated the usefulness of this approach for distinguishing between variants that have structural defects in their endogenous kappa gene from variants that have defects in transacting factors or other steps in the induction pathways.
Subject(s)
B-Lymphocytes/drug effects , Immunoglobulin kappa-Chains/biosynthesis , Interferon-gamma/pharmacology , Lipopolysaccharides/pharmacology , Lymphoma, Non-Hodgkin/pathology , Animals , B-Lymphocytes/metabolism , Gene Expression Regulation/drug effects , Immunoglobulin kappa-Chains/genetics , Lymphocyte Activation/drug effects , Lymphoma, Non-Hodgkin/metabolism , Mice , Neoplasm Proteins/biosynthesis , Recombinant Proteins/biosynthesis , Regulatory Sequences, Nucleic Acid , Stimulation, Chemical , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolismABSTRACT
We have used a genetic approach to study the differentiation of B lymphocytes. Our model system is the induction of membrane immunoglobulin M-positive (mIgM+) cells in the murine B cell tumor, 70Z/3 by three extracellular mediators: lipopolysaccharide (LPS), supernatants from concanavalin A-stimulated rat spleen cells (CAS) and gamma interferon (IFN). The wild-type 70Z/3 cells synthesize constitutively the mu immunoglobulin heavy chain, but the kappa (kappa) light chain is expressed at extremely low levels. Treatment with these three inducers markedly increases kappa synthesis and allows the expression of IgM on the cell surface. We have selected variants which respond aberrantly to LPS and have analyzed their responses to the other inducers. We have analyzed mIgM expression, mu and kappa mRNA and protein levels. Our results show that the level of kappa mRNA is the most sensitive indicator of cellular response to an inducer. The independence of the variant phenotypes demonstrates that the pathways are not identical.
Subject(s)
B-Lymphocytes/pathology , Immunoglobulin M/biosynthesis , Neoplasm Proteins/biosynthesis , Receptors, Antigen, B-Cell/biosynthesis , Animals , Cell Differentiation/drug effects , Cell Line , Gene Expression Regulation/drug effects , Genes , Immunoglobulin M/genetics , Immunoglobulin kappa-Chains/biosynthesis , Immunoglobulin kappa-Chains/genetics , Interferon-gamma/pharmacology , Lipopolysaccharides/pharmacology , Lymphokines/pharmacology , Lymphoma , Mice , Neoplasm Proteins/genetics , Phenotype , RNA, Messenger/analysis , Receptors, Antigen, B-Cell/geneticsABSTRACT
The cultured murine B cell lymphoma, 70Z /3, can be induced to express membrane IgM ( mIgM ) after exposure to lipopolysaccharide (LPS) or T cell-derived factors. The kinetics and magnitude of the responses have been compared in wild type 70Z /3 cells and three variants by using flow cytometric analysis and immunoprecipitation. Wild type 70Z /3 cells respond to LPS more quickly and with twofold greater mIgM than to concanavalin A-induced spleen cell supernatant (CAS). Variants were selected for their abnormal mIgM expression in response to LPS, but individual variants also showed normal, aberrant, or no response to CAS. When cells were induced with suboptimal amounts of LPS and CAS, a synergistic effect on the magnitude of mIgM expression was seen in wild type and variant cells. This suggests that both inducing agents are utilizing some part of a common inductive mechanism. The different responses of the variant cell lines will allow further genetic dissection and comparison of the mIgM expression pathways used in response to LPS and CAS.